1094 NATIONAL CENTER FOR **IMMUNIZATION & RESPIRATORY DISEASES**

Multisystem Inflammatory Syndrome in Children (MIS-C) in Persons Fully Vaccinated with Two Doses of mRNA COVID-19 Vaccine Compared with Persons with Partial or No Vaccination Reported, U.S. National MIS-C Surveillance

Anna R. Yousaf, MD; Allison D. Miller, MPH; Katherine Lindsey, MPH; Michael J. Wu, MSc; Michael Melgar, MD; Laura D. Zambrano, PhD, MPH; Angela P. Campbell, MD, MPH

BACKGROUND

CDC began collecting COVID-19 vaccination status of persons with MIS-C as part of national surveillance in May 2021. We describe and compare MIS-C in fully vaccinated persons with MIS-C in those with partial or no vaccination reported.

METHODS

We identified COVID-19 vaccine age-eligible persons meeting the CDC MIS-C case definition reported by health departments as of September 6, 2022, and divided them into 3 groups:

- **1)** Fully vaccinated (receipt of a 2-dose mRNA primary vaccine series with MIS-C onset ≥28 days after vaccine dose 2 to account for the delay between infection and MIS-C);
- 2) Partially vaccinated (MIS-C onset after dose 1 or <28 days from dose 2 or receipt of Janssen [Johnson & Johnson]; vaccine and;
- 3) No vaccination reported.

RESULTS

- Of 8,898 MIS-C cases reported, 1,485 were vaccine eligible: 89 fully vaccinated, 91 partially vaccinated, and 1,305 with no vaccination reported.
- Those with Non-Hispanic white race/ethnicity were more likely to report full vaccination vs no vaccination (55% vs 43%, p=0.03)
- Shock/receipt of pressors and ICU-level care differed significantly in fully vaccinated vs those with no vaccination reported (32% vs 43%, p=0.04 and 45% vs 59%, p=0.01).
- Twenty-one (2%) of those with no vaccination reported died; no fully or partially vaccinated persons died.

CONCLUSIONS

- Persons who acquire SARS-CoV-2 infection after being fully vaccinated can develop MIS-C, with similar clinical characteristics to those with no vaccination reported.
- A lower and statistically significant percentage of fully vaccinated persons required ICU-level care compared with those with no vaccination reported, and there were no deaths in the fully vaccinated group.
- These data do not account for trends in MIS-C over time, including the influence of circulating SARS-CoV-2 variants on **MIS-C clinical manifestations.**

No MIS-C deaths were reported in fully and partially vaccinated persons compared with 21 deaths in those with no vaccination reported.




Table 2. Multisystem Inflammatory Syndrome in Children Organ Involvement of Persons with No COVID-19 Vaccination Reported **Compared with Partially and Fully Vaccinated Persons**

*Chi Square p<0.05

Fewer persons who develop MIS-C after being fully vaccinated require ICU-level care compared with those with no vaccination reported.

No Partially **Fully Vaccinated** Vaccination Vaccinated Reported (n=89) (n=91) (n=1,305) n (%) n (%) p value¹ n (%) p value¹ 980 (75) 64 (70) 0.311 61 (68) 0.169 Severe cardiovascular² 39 (43) 28 (32) Shock/vaso-559 (43) 0.997 0.036 pressor receipt 22 (25) 293 (23) 25 (28) 0.270 0.621 Severe gastrointestinal³ 768 (59) 55 (60) 55 (62) 0.766 0.584 Severe hematologic⁴ 863 (66) 63 (69) 54 (61) 0.545 0.294 Dermatologic/ mucocutaneous

¹No vaccination reported = comparator group, P-values from Chi square or Fischer's Exact tests and Kruskal-Wallis ²Ventricular dysfunction, pericardial effusion/pericarditis, myocarditis, congestive heart failure, arrhythmia, elevated troponin, elevated BNP or NT-pro BNP ≥ 1,000 pg/mL, shock/receipt of vasopressors, or extracorporeal membranous oxygenation (ECMO)

³Mesenteric adenitis, free fluid, hepatosplenomegaly, colitis/enteritis, cholecystitis/gallbladder abnormalities, or appendicitis/appendiceal changes

⁴Thrombocytopenia, lymphopenia, neutropenia, or thrombosis

5-11 Yrs. 12-15 Yrs. 16-20 Yrs. Male Non-Hispai Non-Hispa White Non-Hispai Asian Non-Hispai Other² Hispanic Obesity Chronic lun disease

race. and "other race

	No Vaccination	Partially Vaccinated (n=91)		Fully Vaccinated (n=89)	
	Reported				
	(n=1,305)				
	n (%)	n (%)	p value ¹	n (%)	p value ¹
ICU-level care ²	768 (59)	45 (50)	0.079	40 (45)	0.010
Hospital length of	5 (4-7)	5 (3-7)	0.514	5 (3-7)	0.133
stay, median, IQR					
(days)					
ICU length of stay,	3 (2-5)	3 (2-5)	0.944	3 (1-4)	0.196
median, IQR (days)					
Death	21 (2)	0 (0)	0.223	0 (0)	0.228

SCAN HERE FOR MORE INFORMATIO Anna R. Yousaf pgy6@cdc.gov

Table 1. Demographic and Clinical Characteristics of Persons with MIS-C with No COVID-19 Vaccination Reported **Compared with Partially and Fully Vaccinated Persons**

	No Vaccination	Partially Vaccinated (n=91)		Fully Vaccinated	
	Reported				
	(n=1,305)			(n=89)	
	n (%)	n (%)	p value ¹	n (%)	p value ¹
	523 (40)	47 (52)	0.030	33 (37)	0.576
	551 (40)	32 (35)	0.187	37 (42)	0.905
	231 (18)	12 (13)	0.272	19 (21)	0.386
	825 (63)	52 (58)	0.297	54 (61)	0.624
nic Black	387 (32)	26 (29)	0.827	18 (22)	0.058
nic	526 (43)	39 (43)	0.631	46 (55)	0.027
nic	34 (3)	1 (1)	0.374	3 (4)	0.656
nic	64 (5)	3 (3)	0.488	4 (5)	0.872
	214 (18)	16 (18)	0.769	12 (15)	0.483
	365 (28)	23 (25)	0.579	18 (20)	0.113
ng	104 (8)	5 (6)	0.395	8 (9)	0.732

No vaccination reported = comparator group, P-values from Chi square or Fischer's Exact tests and Kruska

Race/ethnicity missing for 80 in the vaccine not reported group, 6 in the partially vaccinated group, and 6 in the fully vaccinated group; "Other race" includes American Indian/Alaska Native, Pacific Islander, multiple

Table 3. MIS-C Treatment and Outcomes of Persons with No **COVID-19 Vaccination Reported Compared with Partially and Fully Vaccinated Persons**

LU admission on case report form or receipt of invasive ventilation, vasopressors, or ECMC



